← back to search

Takahiro Higashi

University of Tokyo Health Sciences · JP
Area of research
Oncology · Epidemiology
Research interest
Research interests include Global Cancer Incidence and Screening, Multiple and Secondary Primary Cancers, Gastrointestinal Tumor Research and Treatment, and Sarcoma Diagnosis and Treatment.
h-index
35
citations
4,950
works
366
NIH funding
primary concept
Medicine
email

Recent publications

Trends and current status in anticancer therapy for older patients with non-small cell lung cancer in Japan, 2016-2021.
2026cited by 0position: contributordoi
Reducing Hallucinations and Trade-Offs in Responses in Generative AI Chatbots for Cancer Information: Development and Evaluation Study.
2025cited by 2position: contributordoi
Proposal for a New Classification of Rare Cancers Adopting Updated Histological Tumor Types.
2025cited by 2position: contributordoi
Chondrosarcoma in Japan: an analytic study using population-based National Cancer Registry.
2025cited by 2position: contributordoi
Quality indicators for endometrial cancer care in Japan.
2025cited by 2position: contributordoi
Clinical Features and Prognosis of Malignant Cutaneous Adnexal Tumors: A Retrospective Study Using a Japanese Database.
2025cited by 1position: contributordoi
Epidemiologic Features and Age-Related Differences in Management among Patients with Gastrointestinal Stromal Tumors in Japan: A National Cancer Registry Study.
2025cited by 0position: contributordoi
Revision of quality indicators for cervical cancer and trend analysis of existing indicators in Japan.
2025cited by 0position: contributordoi
Incidence, mortality, survival, and treatment statistics of cancers in digestive organs-Japanese cancer statistics 2024.
2024cited by 32position: contributordoi
Soft-tissue sarcoma in Japan: National Cancer Registry-based analysis from 2016 to 2019.
2024cited by 9position: contributordoi
The accuracy and characteristics of gastric cancer treatment information in the national data of the hospital-based cancer registry.
2024cited by 0position: contributordoi
Retroperitoneal sarcoma: a 10-year follow-up analysis using hospital-based cancer registry data in Japan.
2024cited by 0position: contributordoi
Cost-effectiveness analysis of hospital treatment volume and survival outcomes in endometrial cancer in Japan.
2024cited by 0position: contributordoi
Epidemiology of skin cancer based on Japan's National Cancer Registry 2016-2017.
2023cited by 22position: contributordoi
Time to Treatment Initiation for Six Cancer Types: An Analysis of Data from a Nationwide Registry in Japan.
2023cited by 13position: contributordoi
Differences in the performance of adjuvant chemotherapy between hemodialysis and nonhemodialysis patients.
2023cited by 3position: contributordoi
Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines.
2023cited by 2position: contributordoi
A retrospective study of sentinel lymph node biopsy for skin cancer in Japan: Comparison with breast cancer and evaluation of factors related to its use.
2023cited by 1position: contributordoi
Impact of the COVID-19 pandemic on the diagnosis of cancer in Japan: analysis of hospital-based cancer registries.
2022cited by 36position: contributordoi
Cancer epidemiology and treatment patterns for older persons in Japan: a review of nationwide data and statistics.
2022cited by 9position: contributordoi
Associations Between Adherence to Evidence-Based, Stroke Quality Indicators and Outcomes of Acute Reperfusion Therapy.
2022cited by 9position: contributordoi
Real-world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database.
2022cited by 6position: contributordoi
Family cancer history and smoking habit associated with sarcoma in a Japanese population study.
2022cited by 5position: contributordoi
Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan.
2022cited by 2position: contributordoi
Association between diabetes and adjuvant chemotherapy implementation in patients with stage III colorectal cancer.
2022cited by 2position: contributordoi
How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan.
2022cited by 1position: contributordoi
Cardiac Function Checkup During Trastuzumab Therapy Among Patients With Breast Cancer.
2022cited by 0position: contributordoi
Validation of Identifying Cancer Diagnosis Based on Self-Reported Information in the Japan Nurses' Health Study.
2022cited by 0position: contributordoi
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015  Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.
2021cited by 76position: contributordoi
Coverage of the hospital-based cancer registries and the designated cancer care hospitals in Japan.
2021cited by 27position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 12 papers (2020–2025)Kunihiro Nishimura · National Cerebral and Cardiovascular Center3 papers (2019–2022)Satoru Motoyama · Akita University3 papers (2019–2021)Dai Ogata · Peking University Cancer Hospital3 papers (2023–2025)Naoya Yamazaki · The University of Osaka3 papers (2023–2025) · 3 papers (2022–2025)Kenjiro Namikawa · The University of Osaka3 papers (2023–2025)Akira Kawai · Shiga University3 papers (2022–2025)Satoru Nagase · Tohoku University2 papers (2024–2025)Eisuke Kobayashi · National Cancer Center2 papers (2022–2025)Eiji Nakano · Kobe University Hospital2 papers (2023–2025)Kota Katanoda · National Cancer Centre Japan2 papers (2022–2022) · 2 papers (2020–2021)Shogo Wada · Tokyo Medical and Dental University2 papers (2023–2025)Ryoko Rikitake · University of Tokyo Health Sciences2 papers (2025–2025) · 2 papers (2025–2025)Mikio Mikami · Keio Gijuku Daigaku - Shinanomachi Campus2 papers (2024–2025)Taisuke Ishii · National Cancer Centre Japan2 papers (2023–2025)Wataru Yamagami · Keio University2 papers (2024–2025)Chigusa Morizane · National Cancer Center2 papers (2025–2025)